Evidence map›Paper›PMID 42670053›Full record

ArticleAnimal models and experimental medicine2026

Refining OVCAR-3 xenograft models of peritoneal carcinomatosis in nu/nu mice: Comparative intraperitoneal implantation strategies and the role of basement membrane matrix.

M Teresa Perelló-Trias, Antonio Jose Serrano-Muñoz, Juan J Segura-Sampedro, Adriana M Quintero-Duarte, Joana M Ramis, Marta Monjo

Abstract read
In one paragraph

Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M Teresa Perelló-TriasGroup of Cell Therapy and Tissue Engineering (TERCIT), Research Institute on Health Sciences (IUNICS), University of the Balearic Islands (UIB), Palma, Spain.
Antonio Jose Serrano-MuñozGroup of Cell Therapy and Tissue Engineering (TERCIT), Research Institute on Health Sciences (IUNICS), University of the Balearic Islands (UIB), Palma, Spain.ORCID https://orcid.org/0009-0005-7867-8940
Juan J Segura-SampedroGeneral & Digestive Surgery Service, Hospital Universitario la Paz (IdiPAZ), Madrid, Spain.ORCID https://orcid.org/0000-0003-0565-3791
Adriana M Quintero-DuarteHealth Research Institute of the Balearic Islands (IdISBa), Palma, Spain.
Joana M RamisGroup of Cell Therapy and Tissue Engineering (TERCIT), Research Institute on Health Sciences (IUNICS), University of the Balearic Islands (UIB), Palma, Spain.ORCID https://orcid.org/0000-0001-9109-8362
Marta MonjoGroup of Cell Therapy and Tissue Engineering (TERCIT), Research Institute on Health Sciences (IUNICS), University of the Balearic Islands (UIB), Palma, Spain.ORCID https://orcid.org/0000-0002-2731-9527

Funding

Direcció General d'Investigació and Conselleria d'Investigació, Govern Balear FPI/004/2021Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, co-funded by the ERDF PI20/00115Ministerio de Universidades, Gobierno de España FPU22/00610
6 · The paper itself

Abstract

backgroundOvarian cancer (OC) is often diagnosed at advanced stages, with extensive peritoneal carcinomatosis (PC) and poor prognosis. Although intraperitoneal drug delivery systems (iDDS) are promising for targeting residual microscopic disease after cytoreductive surgery, reproducible murine PC models remain limited. We compared two OVCAR-3-based intraperitoneal engraftment strategies (diffuse vs. localized) and assessed the impact of inoculum density and basement membrane extract (BME) supplementation to identify a robust model for iDDS evaluation.

methodsImmunodeficient female nu/nu mice were engrafted with luciferase-expressing OVCAR-3 cells. For localized implantation, 1 × 10

resultsIn the localized model, no differences were detected between 1 × 10

conclusionsThe intraperitoneal injection model with BME more accurately reproduced human PC progression and distribution, providing a platform for preclinical testing of localized iDDS.

Indexed as

bioluminescence imagingintraperitoneal implantationovarian cancerOVCAR‐3peritoneal carcinomatosisxenograft model

Identifiers

PMID42670053
PMCPMC13527296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.